Using 3D technology to improve diagnosis and treatment of primary liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of three-dimensional (3D) visualization technology in the diagnosis and treatment of primary liver cancer. Patients will undergo surgical treatment guided by high-quality thin-slice CT images reconstructed into 3D models, which aim to enhance surgical planning and navigation. The study compares outcomes between patients receiving 3D-guided surgery and those receiving standard CT-guided surgery. The goal is to reduce recurrence rates and improve surgical success through better preoperative planning and intraoperative guidance.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with primary liver cancer clinically diagnosed preoperatively (tumor ≥3cm to ≤10cm, diagnostic criteria: Primary liver cancer Diagnosis and Treatment Code 2019 edition);
* No tumor thrombi formation and distant metastasis were found in the imaging data;
* Child-Pugh grading standard of liver function was GRADE A or B;
* 18-66 years old;
* Complete clinical case data;
* all patients underwent surgical treatment;
* Voluntarily participate in the study and sign the informed consent.

Exclusion Criteria:

* There are basic diseases that cannot tolerate surgery (such as severe cardiopulmonary cerebral renal insufficiency);
* Preoperative imaging examination found cancer thrombus in main portal vein and branches, common hepatic vein and branches, main hepatic vein and branches and inferior vena cava;
* planned pregnancy, unplanned pregnancy and pregnancy;
* Preoperative child-Pugh grading standard of liver function was Grade C.
* Disease researchers that the investigator considers inappropriate to participate in this clinical trial.

Where it's running

• Mi-3dvs
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Chihua Fang, MD
• Email: fangchihua@smu.edu.cn
• Phone: 13609700805

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using tumor infiltrating lymphocytes to treat advanced liver and pancreatic cancers

  This study is testing a new treatment using immune cells from tumors to see if it can help people with advanced liver and pancreatic cancers who haven't responded to regular therapies.

  Recruiting Early Phase 1 Shanghai Juncell Therapeutics · Shanghai, Shanghai Municipality · NCT05098197

• Using virtual reality to help manage pain in GI cancer patients

  This study is testing if virtual reality can help people with GI cancer manage their severe abdominal pain better than standard treatments.

  Recruiting Cedars-Sinai Medical Center · Los Angeles, California · NCT04907643

• MTS105 treatment for advanced liver cancer

  This study is testing a new treatment called MTS105 for people with advanced liver cancer to see if it can help their immune system fight the cancer after other treatments haven't worked.

  Recruiting Phase 1 Peking University · Beijing · NCT06689540

• Exploring early-stage lung cancer with different characteristics using multi-omics

  This study is trying to understand the different types of early-stage lung cancer by looking at their unique characteristics to see if this can help predict outcomes and find new treatment options for patients.

  Recruiting Central South University · Changsha, Hunan · NCT06699979

• Plasma methylation test for detecting liver cancer recurrence (GNB4 and Riplet)

  This test sees if a blood-based methylation assay measuring GNB4 and Riplet can detect return of primary liver cancer in people who had hepatectomy, liver transplant, ablation, or TACE.

  Recruiting Wuhan Ammunition Life-tech Co., Ltd · Wuhan, Hubei · NCT07466602

• Using contrast-enhanced ultrasound to check Y-90 radioembolization response in liver cancer

  This will test whether contrast-enhanced ultrasound (CEUS) can show treatment response to Y‑90 radioembolization in people with newly diagnosed hepatocellular carcinoma who are scheduled for TARE.

  Recruiting Phase 2 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07145801

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.